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Abstract
Objective: To examine the long-term effect of CPAP on carotid artery intima-media thickness (IMT) in patients with
Obstructive sleep apnea syndrome(OSAS).
Methods: A prospective observational study over 12 months at a teaching hospital on 50 patients newly
diagnosed with OSAS who received CPAP or conservative treatment (CT). Carotid IMT was assessed with B-mode
Doppler ultrasound from both carotid arteries using images of the far wall of the distal 10 mm of the common
carotid arteries at baseline, 6 months and 12 months.
Measurements and results [mean (SE)]: Altogether 28 and 22 patients received CPAP and CT respectively
without significant differences in age 48.8(1.8) vs 50.5(2.0)yrs, BMI 28.2(0.7) vs 28.0(1.2)kg/m2, ESS 13.1(0.7) vs 12.7
(0.6), AHI 38(3) vs 39(3)/hr, arousal index 29(2) vs 29(2)/hr, minimum SaO2 75(2) vs 77(2)% and existing co-
morbidities. CPAP usage was 4.6(0.3) and 4.7(0.4)hrs/night over 6 months and 1 year respectively. Carotid artery IMT
at baseline, 6 months, and 12 months were 758(30), 721(20), and 705(20)micron for the CPAP group versus 760(30),
770(30), and 778(30)micron respectively for the CT group, p = 0.002.
Among those free of cardiovascular disease(n = 24), the carotid artery IMT at baseline, 6 months and 12 months
were 722(40), 691(40), and 659(30)micron for the CPAP group (n = 12) with usage 4.5(0.7) and 4.7(0.7) hrs/night
over 6 months and 12 months whereas the IMT data for the CT group(n = 12) were 660(20), 685(10), and 690(20)
micron respectively, p = 0.006.
Conclusions: Reduction of carotid artery IMT occurred mostly in the first 6 months and was sustained at 12
months in patients with reasonable CPAP compliance.
Background
Obstructive sleep apnea syndrome (OSAS) is character-
ized by repetitive episodes of upper airway obstruction
causing daytime sleepiness, impaired cognitive function
and poor health status [1]. Untreated OSA is associated
with increased risks of developing fatal and non-fatal
cardiovascular events [2,3]. Three large prospective
cohort studies have shown that untreated OSA is an
independent risk factor for all-cause mortality after
long-term follow-up [4-6]. Untreated OSA is also
associated with dysglycemia, systemic inflammation,
endothelial dysfunction, platelet activation, and other
cardiovascular consequences such as cardiac arrhyth-
mias especially atrial fibrillation (AF), coronary artery
disease, asymptomatic early atherosclerosis, and silent
brain infarction [7].
In recent years, carotid artery IMT, measured by B-
mode ultrasound, has been shown to be a highly repro-
ducible test and correlate well with traditional vascular
risk factors. It may predict the likelihood of acute cor-
onary events and stroke in asymptomatic healthy sub-
jects [8,9]. Several studies have shown that the severity
of OSA is independently related to the carotid artery
IMT, with the severity of OSA-related hypoxemia more
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[10,11]. One randomized controlled trial (RCT) has
s h o w nt h a tc o n t i n u o u sp o s i t i v ea i r w a yp r e s s u r e( C P A P )
(n = 12) over 4 months could reduce carotid artery IMT
in patients with severe OSAS free of existing cardiovas-
cular diseases versus controls (n = 12) [12], but another
recent RCT of 3 months treatment duration has failed
to show any significant change in carotid artery IMT
when comparing CPAP (n = 43) versus sham CPAP (n
= 43) [13]. Hence it remains unknown whether CPAP
can consistently reduce the carotid artery IMT in
patients with OSAS or to a greater magnitude over a
longer treatment period. This study examined the long-
term effects of CPAP versus conservative treatment
(CT) on carotid artery IMT over a period of 1 year.
Methods
We conducted a prospective observational study of the
treatment effects on carotid artery IMT in patients
newly diagnosed with OSAS. OSAS, as defined by an
overnight polysomnography (PSG) showing apnea-
hypopnea index (AHI) ≥ 5/hour of sleep plus excessive
daytime sleepiness or two of the following symptoms:
choking or gasping during sleep, recurrent awakenings
from sleep, unrefreshed sleep, daytime fatigue, and
impaired concentration [14,15]. The patients were
recruited from the Respiratory Clinic, Prince of Wales
Hospital, Hong Kong. The inclusion criteria of the study
included age 20 to 80 yrs, and AHI ≥5h ro nP S Gw i t h
symptoms of OSA as described above. The exclusion
criteria included patients having problems staying awake
during driving, professional drivers, shift work, recent
myocardial infarction, unstable angina, underlying
malignancy, and treatment of hyperlipidemia with sta-
tins or other lipid-lowering agents. Our study was
approved by the Ethics Committee of the Chinese Uni-
versity of Hong Kong (CRE-2005.135) and appropriate
informed written consent was obtained from the
subjects.
Sleep assessment
Overnight diagnostic PSG (Healthdyne Alice 4, USA)
was performed for every subject recording electroence-
phalogram(EEG), electro-oculogram, submental electro-
myogram (EMG), bilateral anterior tibial EMG,
electrocardiogram, chest and abdominal wall movement
by inductance plethysmography, airflow measured by a
nasal pressure transducer [PTAF2, Pro-Tech, Woodin-
ville, WA, USA] and supplemented by an oral thermis-
ter, and finger pulse oximetry as described in our
previous studies [15,16]. Sleep stages were scored
according to standard criteria by Rechtshaffen and Kales
[17]. Apnea was defined as cessation of airflow for > 10
seconds and hypopnea as a reduction of airflow of ≥
50% for > 10 seconds plus an oxygen desaturation of >
3% or an arousal. An arousal was scored if there was a 3
sec or longer abrupt shift in EEG frequency to alpha or
theta or >16 Hz, following at least 10 sec of sleep, and if
arising in REM there must be a rise in EMG tone [18].
Following confirmation of OSA, all patients were
arranged to undergo an attended overnight autoCPAP
titration on the second night of the sleep study. All
patients were given a basic CPAP education program by
our respiratory nurse supplemented by education bro-
chure [15,16]. The nurse would fit a comfortable CPAP
mask from a wide range of selection for every patient,
who was then given a short trial of CPAP therapy with
the Autoset (ResMed, Sydney, Australia) CPAP device
for approximately 30 minutes for acclimatization in the
afternoon. Following the overnight autoCPAP titration
study, each patient was interviewed by the physician on
duty and invited to participate in the serial carotid IMT
study.
Group 1 (CT)
After confirmation of significant OSAS and completion
of overnight attended autoCPAP titration, patients who
were not keen to start CPAP yet were encouraged to a)
avoid sleep deprivation by having sufficient hours of
sleep every night; b) sleep in lateral positions; c) avoid
sedatives and alcohol consumption 4 hours before sleep;
and d) lose weight by exercise and diet where appropri-
ate [19].
Group 2 (CPAP)
In addition to the usual advice as given to group 1,
patients who had agreed to commence CPAP treatment
after completing an overnight autoCPAP titration were
subsequently prescribed CPAP device with a time coun-
ter recording machine run time. The CPAP pressure for
each patient was set at the minimum pressure needed to
abolish snoring, obstructive respiratory events, and air-
flow limitation for 95% of the night as determined by
the overnight AutoSet CPAP titration study [15,16].
Carotid artery IMT
Was measured at baseline, 6 months, and 12 months for
patients in both groups. The patients were followed up
at the Respiratory clinic at 1, 3, 6 and 12, months
whereas objective CPAP usage was measured from the
time counter for group 2.
Carotid artery IMT was assessed by B-mode ultra-
sound scanning with an 11-MHz linear phase array
transducer (Sonos 5500, Hewlett-Packard, Andover,
Massachusetts, USA). Bilateral IMT measurements were
obtained at the distal 10 mm of common carotid artery
as described by our group previously [20,21]. The IMT
was defined as the distance between the leading edge of
the luminal echo to that of the media/adventitia echo
and analyzed with a computerized edge-detection sys-
tem (Q-Lab5.0, Xcelera, Phillips, USA). Three end-
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for the mean IMT, and the average reading from these
3 frames was calculated for both right and left carotid
arteries. The sole carotid scan operator (QS) was
blinded to the clinical treatment status of the studied
subjects and was not involved in the clinical assessment
[20,21].
Blood pressure (BP) was measured in the right arm
after at least 5 minutes of rest using a standard sphyg-
momanometer and the Korotkoff sound V was used as
the indicator for the diastolic BP at baseline before PSG
and at clinic visits at 6 months and 12 months.
Statistical analysis
The sample size was estimated by the Power Analysis
and Sample Size for Windows software (PASS 2000,
NCSS, Kaysville, Utah). Based on the findings of Drager
et al [12], group sample sizes of 28 would achieve 80%
power to detect a difference of carotid IMT between the
treatment and control groups (645 +/- 95 versus 740
+/−150 [micron]) at a significance level (alpha) of 0.05,
using a two-sided paired Student’s t test.
The primary end-point was the change in carotid
artery IMT. For comparisons between the 2 groups at
each time point, unpaired t-test was used for normally
distributed variables and Mann-Whitney U test for
non-normally distributed variables. To compare the
measurements before and after CPAP treatment, paired
t-test was used for normally distributed variables and
Wilcoxon’s signed rank test for non-normally distribu-
ted variables. Two-factor ANOVA (group versus time)
with repeated measures on the factor time (baseline
minus treatment) was used to test for the effect of
CPAP versus CT. Data are expressed as mean ± SE
unless stated otherwise. A p-value of < 0.05 is consid-
ered significant.
Results
We invited 100 patients with newly confirmed OSAS
who had met the study criteria to participate in the
serial carotid IMT study after completing PSG and an
overnight autoCPAP titration. However, 50 eligible
patients either refused to participate (n = 20) or could
not take time off (n = 30) for completion of the serial
carotid IMT study (Figure 1). There were no significant
differences in demographics between patients who com-
pleted the carotid IMT study versus those who did not
(Table 1). Among the remaining 50 patients who had
completed the carotid IMT study, 22 received CT
whereas 28 received CPAP treatment. The demo-
graphics and severity of OSA between the two groups
were similar (Table 2). The subjects did not alter the
dosage of their medications during the study.
Comparisons of changes of parameters between CPAP
group and CT group
The objective CPAP usage were 4.6(0.3) and 4.7(0.4)
hrs/night for the CPAP group over 6 months and 1 year
respectively. The serial mean carotid artery IMT at base-
line, 6 months and 12 months were 757.5(30), 720.9(20)
and 704.5(20)micron for the CPAP group (Figure 2)
whereas the serial IMT data for the CT group were
760.0(30), 769.8(30), and 777.7(30)micron respectively, p
= 0.002 (ANOVA for repeated measures) (Table 3 and
Figure 2).
The changes in mean carotid artery IMT between
baseline and 6 months were −36.6 (10) versus 9.8(10)
micron for the CPAP and CT group respectively, 95%CI
(−77, −15.8 micron), p = 0.004. The changes in mean
carotid artery IMT between baseline and 12 months
were −53(20) versus 17.7(10) micron for the CPAP and
the CT group respectively, 95%CI (−114.8, −26.7
micron), p = 0.002. The changes in mean carotid artery
IMT between 6 months and 12 months were −16.4(10)
versus 8(10) micron for the CPAP and the CT group
respectively, 95%CI (−56, 72.2 micron), p = 0.127.
There was no correlation between objective CPAP
usage and changes in carotid IMT at 6 months, r =
−0.185 (p = 0.375) and at 12 months, r = −0.018 (p =
0.930).
Comparisons of changes of parameters between CPAP
group and CT group among those free of existing
cardiovascular disease (excluding smoking and alcohol
intake)
Among those free of existing cardiovascular disease (n =
24), there were no significant differences in baseline
demographics and severity of OSAS between the two
groups including the absence of carotid plaques (Table
4). The mean carotid artery IMT at baseline, 6 months
and 12 months were 721.7(40), 690.8(40), and 659.2(30)
micron for the CPAP group (n = 12) with objective
CPAP usage 4.5(0.7) and 4.7(0.7) hrs/night over 6
months and 12 months (Figure 3) whereas the corre-
sponding carotid IMT data for the CT group (n = 12)
were 660.0(20), 684.6(10) and 690.0(20) micron respec-
tively, p = 0.006 (ANOVA for repeated measures)
(Table 5 and Figure 3).
The changes in mean carotid artery IMT between
baseline and 6 months were −30.8 (10) versus 24.6(10)
micron for the CPAP and CT group respectively, 95%CI
(−89.4, −21.4 micron), p = 0.003. The changes in mean
carotid artery IMT between baseline and 12 months
were −62.5(20) versus 30(20) micron for the CPAP and
CT group respectively, 95%CI (−155.4, −29.6 micron), p
= 0.006. The changes in mean carotid artery IMT
between 6 months and 12 months were −31.7(20) versus
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tively, 95%CI (−87.9, 13.7 micron), p = 0.144.
Discussion
In a group of 50 symptomatic patients newly diagnosed
with severe OSAS, this prospective observational study
has shown that CPAP treatment (n = 28) resulted in sig-
nificant reduction in carotid artery IMT compared to
those who had opted for conservative treatment (CT, n
= 22) over a study period of 12 months. Most of the
reduction in carotid artery IMT when comparing CPAP
against CT group appeared to have occurred within the
first 6 months of treatment whereas there was no signif-
icant change from 6 to 12 months while the patients
had maintained reasonable CPAP usage objectively
throughout the study. Similar observations were noted
in patients with and without existing cardiovascular
diseases.
Data from the Sleep Heart Health Study (SHHS) have
shown that modest to severe levels of OSA are asso-
ciated with an approximately threefold increased risk of
ischemic stroke in community-dwelling men [22]. The
Wisconsin Sleep Cohort Study has provided prospective
evidence that OSA is related to significantly increased
odds of suffering a stroke over the next 4 years after
adjustment for age and gender [23]. In an observational
sleep clinic study, Yaggi et al [24] have shown that OSA
significantly increases the risk of stroke or death from
any cause and the increase is independent of other
known risk factors. Patients with stroke and OSA have
an increased risk of early death over 10 years [25],
whereas sleep apnea is significantly associated with
increased risk of stroke among patients with coronary
artery disease over a follow-up period of 10 years [26].
There are several proposed mechanisms linking OSA
and stroke. Snoring-induced vibrational injury may lead
to carotid atherosclerosis [27]. There is a strong associa-
tion between OSA and AF [28]. Platelet activation [16]
and silent brain infarction were also more common in
patients with moderate to severe OSA than in controls
[29]. OSA may accelerate atherosclerosis through the
effect of hypertension and other mechanisms such as
insulin resistance, diabetes, and dyslipidemia. In addi-
tion, OSA can induce direct proatherogenic effects
through the mechanisms of systemic inflammation, oxi-
dative stress, vascular smooth cell activation, increased
Figure 1 Patient profile. Among the 20 eligible patients who did not consent for the study, 14 had started CPAP treatment at home whereas
6 were subsequently referred for treatment with the mandibular advancement device. Among the 30 patients who had agreed to join the
study initially, 22 were started on home CPAP whereas the other 8 opted for conservative treatment. However these 30 patients were unable to
return for serial measurements of carotid IMT due to their busy work schedule.
Hui et al. Respiratory Research 2012, 13:22
http://respiratory-research.com/content/13/1/22
Page 4 of 10adhesion molecule expression, monocyte/lymphocyte
activation, increased lipid loading in macrophages, lipid
peroxidation, and endothelial dysfunction [30].
In recent years, carotid artery IMT has been well
accepted as a non-invasive tool which may predict the
likelihood of acute coronary events and stroke in asymp-
tomatic healthy subjects [8,9]. Carotid artery IMT has
been applied by several research groups to study
different OSA populations. Although cross-sectional
analysis of the SHHS has found no evidence that mild
to moderate SDB is associated with subclinical athero-
sclerosis [31], data from other groups have suggested
that OSA may lead to early atherosclerosis, as reflected
by increase in carotid artery IMT and occurrence of pla-
ques, in the absence of any significant comorbidity
[32-34]. In one series of OSA patients, severity of
Table 1 Comparisons of baseline parameters between patients who completed the 12-month carotid IMT study and
those who did not
Completed study (n = 50) Did not complete study (n = 50) P value
Male/Female 41/9 43/7 0.786
Age (yrs) 49.5 (1.4) 47.8 (1.7) 0.417
Body mass index (kg/m²) 28.1 (0.6) 28.2 (0.7) 0.954
Neck circumference (cm) 39.6 (0.5) 39.4 (0.5) 0.703
Systolic blood pressure (mmHg) 140.3 (3.1) 136.5 (3.1) 0.384
Diastolic blood pressure (mmHg) 80.6 (1.8) 79.8 (1.9) 0.749
Waist circumference (cm) 96.8 (1.6) 98.0 (1.7) 0.611
Hip circumference (cm) 101.6 (1.3) 102.6 (1.4) 0.602
Smoking status
Non smoker 33 36 0.666
Smoker 17 14
Alcoholic consumption
Non drinker 23 21 0.840
Drinker 27 29
ESS (0-24) 13.1 (0.7) 12.7 (0.6) 0.663
Congestive Heart Failure
Yes 3 0 0.242
No 47 50
Diabetes
Yes 6 8 0.774
No 44 42
Hypertension
Yes 23 18 0.416
No 27 32
Carotid plaque in baseline study
Yes 12 10 0.810
No 38 40
AHI (events per hr) 37.7 (3.0) 38.5 (3.4) 0.854
REM-AHI (events per hr) 35.9 (4.3) 33.1 (4.3) 0.652
Non-REM-AHI (events per hr) 37.8 (3.1) 38.6 (3.5) 0.878
Minimum SaO2 (%) 74.7 (2.2) 76.7 (2.2) 0.530
Mean SaO2 (%) 93.0 (0.6) 93.0 (0.6) 0.980
Arousal index (per hr of sleep) 29.3 (2.0) 28.8 (2.2) 0.857
Percentage of sleep time with SaO2<90% 13.7 (3.1) 7.5 (1.6) 0.081
Snoring/TST (%) 14.2 (3.9) 23.7 (4.0) 0.102
Sleep efficiency (%) 83.4 (1.5) 79.9 (1.8) 0.141
Mean Carotid IMT (micron) 758.6 (20) 742.6 (20) 0.573
Data expressed as mean (SE). TST = total sleep time
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tors for carotid wall hypertrophy whereas plaque occur-
rence without known cardiovascular disease was also
related to the amount of oxygen desaturation regardless
of their BP status [33]. OSA-related hypoxia and sys-
temic inflammation might be associated with progres-
sion of atherosclerosis and increased risk of
cardiovascular morbidity [34]. Another study has
demonstrated a relationship between lipid peroxidation,
carotid artery IMT, and intermittent hypoxia in non-
obese OSA patients [35] whereas in patients with mini-
mally symptomatic OSA, diverse properties of endothe-
lial function are impaired and arterial stiffness is
increased [36]. To date, only one RCT with a small sam-
ple size has shown that CPAP therapy (n = 12) over 4
months could reduce carotid IMT in patients with
severe OSAS free of existing cardiovascular diseases ver-
sus controls (n = 12) (mean changes of −62 vs 8 micron
for the two groups respectively, p = 0.02) [12].
In this study, there were significant differences when
comparing the changes in carotid IMT at 6 months
[-36.6 (10) versus 9.8(10)micron] and at 12 months [-53
(20) versus 17.7(10) micron] respectively from baseline
between CPAP and CT groups. The magnitude of
reduction in carotid IMT with CPAP was similar to
those patients with OSAS with and without existing car-
diovascular disease who received CPAP treatment. A
clinical trial comparing rosuvastatin vs placebo among
984 low risk subjects showed no significant difference in
the rate of mean maximum carotid IMT progression
after 6 months (2.3 vs 10.6 micron/year, p = 0.34). How-
ever, carotid IMT progression rates were significantly
different when comparing rosuvastatin vs placebo at 12
months, (3.2 vs 13.3 micron/year, p = 0.049) whereas
the divergence grew with further follow-up (−0.9 vs 13.1
micron/year at 18 months and -1.4 vs 13.1 micron/year
after 24 months of treatment, p < 0.001 for both time
points) [37].
Although we did not find any significant correlation
between objective CPAP usage and carotid IMT in this
study, variability in the individual response may be
related to the severity of OSA (AHI, hypoxemia) and
CPAP compliance. Although the changes in carotid
IMT with CPAP (n = 43) versus sham CPAP (n = 43)
were not significant in the whole study population by
Sharma et al [13], a subgroup analysis among those (n =
Table 2 Comparison of baseline parameters between







Male/Female 25/3 16/6 0.157
Age (yrs) 48.8 (1.8) 50.5 (2.0) 0.526
Body mass index (kg/m²) 28.2 (0.7) 28.0 (1.2) 0.875
Neck circumference (cm) 40.5 (0.7) 38.5 (0.8) 0.060
Waist circumference (cm) 97.9 (1.9) 95.3 (2.8) 0.437
Hip circumference (cm) 102.2 (1.4) 100.8 (2.3) 0.589
Cholesterol (mmol/l) 5.8 (0.4) 5.2 (0.2) 0.180
HDL Cholesterol (mmol/l) 1.3 (0.1) 1.3 (0.1) 0.923
LDL Cholesterol (mmol/l) 3.3 (0.3) 3.0 (0.2) 0.449
Triglycerides (mmol/l) 3.3 (1.6) 2.2 (0.5) 0.477
Fasting plasma glucose (mmol/l) 5.2 (0.2) 5.5 (0.2) 0.223
Smoking status
Non smoker 20 13 0.386
Smoker 8 9
Alcoholic consumption
Non drinker 14 9 0.577
Drinker 14 13
ESS (0-24) 13.4 (0.9) 12.7 (1.0) 0.603
Congestive Heart Failure
Yes 0 3 0.079
No 28 19
Diabetes Mellitus
Yes 3 3 1.000
No 25 19
Hypertension
Yes 14 9 0.577
No 14 13
On anti-hypertensive drugs
Yes 14 8 0.166
No 14 14
On diabetic drugs
Yes 2 1 1.000
No 26 21
Carotid plaque in baseline study
Yes 7 5 1.000
No 21 17
Systolic blood pressure (mmHg) 140.8 (3.2) 139.7 (6.1) 0.873
Diastolic blood pressure (mmHg) 81.7 (2.1) 79.1 (3.4) 0.497
AHI (events per hr) 39.0 (3.6) 36.1 (5.1) 0.633
REM-AHI (events per hr) 39.1 (6.5) 32.5 (5.7) 0.459
Non-REM-AHI (events per hr) 39.0 (3.7) 36.2 (5.3) 0.662
Minimum SaO2 (%) 74.7 (2.1) 74.8 (4.2) 0.983
Mean SaO2 (%) 93.7 (0.4) 92.1 (1.2) 0.209
Arousal index (per hr of sleep) 31.1 (2.4) 27.1 (3.4) 0.331
Percentage of sleep time with
SaO2<90%
11.1 (2.7) 17.0 (6.3) 0.399
Snoring/TST (%) 11.8 (4.6) 18.5 (7.7) 0.435
Table 2 Comparison of baseline parameters between
patients on CPAP and Conservative treatment (CT)
(Continued)
Sleep efficiency (%) 82.5 (2.0) 84.5 (2.3) 0.513
Mean carotid IMT (micron) 757.5 (30) 760.0 (30) 0.952
Data expressed as mean (SE)
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cant reduction in carotid IMT (34 vs 14 micron, p <
0.05) when comparing CPAP vs sham CPAP treatment
over 3 months.
This study is limited by the fact that it was not a RCT
as it would not be ethical to withhold CPAP treatment
for symptomatic patients with severe OSAS for a 1-year
study in our locality. Only 50% of eligible OSA patients
had participated in this study although the demo-
graphics and severity of OSA between those who parti-
cipated in this study were similar to those who did not.
Likewise patients who received CPAP and those who
opted for CT were similar in terms of demographics
and baseline severity of OSA. Lastly only baseline data
of glucose, lipids and carotid plaques were available and
we did not have serial data to assess the treatment
effects.
Conclusion
In summary, this prospective observational study has
shown that CPAP treatment resulted in significant
reduction in carotid artery IMT whereas no significant
change was noted among those who opted for conser-
vative treatment over a study period of 1 year. Reduc-
tion in carotid artery IMT within the CPAP group
occurred mostly within the first 6 months of treatment
in patients with and without existing cardiovascular
diseases and the reduction well maintained at 12
months in patients with reasonable CPAP compliance.
Patients newly diagnosed with OSAS should be
Figure 2 Shows the data plots of OSA patients on CPAP (n = 28) and those on conservative treatment (n = 22). The serial mean carotid
artery IMT at baseline, 6 months and 12 months were 757.5(30), 720.9(20) and 704.5(20)micron for the CPAP group versus 760.0(30), 769.8(30),
and 777.7(30)micron respectively for those on conservative treatment, p = 0.002 (ANOVA for repeated measures).
Table 3 Repeated measures comparisons of serial parameters between CPAP and CT at baseline, 6 months and 12
months
CPAP (n = 28) CT (n = 22) P-value
Baseline 6 m 12 m Baseline 6 m 12 m
Neck circumference (cm) 40.5 (0.7) 40.2 (0.6) 40.2 (0.7) 38.5 (0.8) 38.2 (0.8) 38.5 (0.8) 0.819
Waist circumference (cm) 97.9 (1.9) 98.0 (1.6) 97.9 (1.7) 95.3 (2.8) 93.2 (2.9) 94.7 (2.9) 0.260
Hip circumference (cm) 102.2 (1.4) 104.0 (1.5) 105.2 (1.3) 100.8 (2.3) 102.5 (2.2) 102.7 (2.1) 0.653
Body mass index (kg/m²) 28.2 (0.7) 28.6 (0.7) 28.3 (0.8) 28.0 (1.2) 27.7 (1.1) 27.9 (1.2) 0.042
Systolic BP (mmHg) 140.8 (3.2) 129.0 (3.6) 130.7 (3.6) 138.4 (5.4) 135.9 (5.4) 136.1 (5.2) 0.593
Diastolic BP (mmHg) 81.7 (2.1) 82.3 (2.1) 83.3 (2.1) 78.6 (3.0) 84.9 (2.9) 83.8 (3.7) 0.412
ESS (0-24) 13.4 (0.9) 8.4 (0.8) 8.2 (1.0) 12.7 (1.0) 10.2 (1.2) 10.3 (1.5) 0.110
CPAP usage (hrs/night) N/A 4.6 (0.3) 4.7 (0.4) N/A N/A N/A N/A
Mean carotid IMT (micron) 757.5 (30) 720.9 (20) 704.5 (20) 760.0 (30) 769.8 (30) 777.7 (30) 0.002
Values are expressed as mean (SE)
The p-values of BP trends from baseline to 12 months within the CPAP group are as follows: systolic BP, p = 0.013; diastolic BP, p = 0.573
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and alcohol consumption) who completed serial carotid IMT measurements between CPAP and CT group
CPAP (n = 12) CT (n = 12) P value
Male/Female 11/1 9/3 0.590
Age (yrs) 44.3 (2.1) 48.5 (1.7) 0.135
Body mass index (kg/m²) 27.4 (1.1) 25.9 (1.1) 0.357
Neck circumference (cm) 40.0 (1.1) 37.6 (1.0) 0.127
Waist circumference (cm) 96.3 (3.2) 91.9 (2.9) 0.320
Hip circumference (cm) 101.7 (2.2) 97.5 (2.1) 0.179
Systolic blood pressure (mmHg) 139.9 (3.6) 129.7 (6.5) 0.164
Diastolic blood pressure (mmHg) 81.7 (2.7) 75.7 (3.2) 0.160
Cholesterol (mmol/l) 5.8 (0.5) 5.4 (0.4) 0.535
HDL Cholesterol (mmol/l) 1.5 (0.3) 1.2 (0.1) 0.331
LDL Cholesterol (mmol/l) 3.7 (0.4) 3.4 (0.3) 0.548
Triglycerides (mmol/l) 1.3 (0.3) 1.8 (0.3) 0.338
Fasting plasma glucose (mmol/l) 5.2 (0.3) 5.1 (0.1) 0.676
ESS (0-24) 12.7 (1.0) 11.5 (1.3) 0.477
Smoking status
Non smoker 10 8 0.640
Smoker 2 4
Alcoholic consumption
Non drinker 7 5 0.684
Drinker 5 7
AHI (events per hr) 36.3 (6.5) 35.5 (6.6) 0.929
REM-AHI (events per hr) 34.4 (6.5) 30.5 (7.6) 0.712
Non-REM-AHI (events per hr) 36.4 (6.8) 35.7 (6.7) 0.942
Minimum SaO2 (%) 77.0 (3.4) 80.0 (2.9) 0.509
Mean SaO2 (%) 94.2 (0.7) 93.9 (0.9) 0.827
Arousal index (per hr of sleep) 29.1 (4.8) 26.8 (5.1) 0.746
Percentage of sleep time with SaO2<90% (%) 10.3 (4.7) 7.6 (3.2) 0.645
Snoring/TST (%) 16.2 (7.7) 7.0 (3.2) 0.510
Sleep efficiency (%) 81.9 (3.0) 81.6 (3.7) 0.943
Mean carotid IMT (micron) 721.7 (40) 660.0 (20) 0.153
Figure 3 Shows the data plots of OSA patients free of existing cardiovascular diseases (excluding smoking and alcohol consumption).T h e
mean carotid artery IMT at baseline, 6 months and 12 months were 721.7(40), 690.8(40) and 659.2(30) micron for the CPAP group (n = 12) versus
660.0(20), 684.6(10) and 690.0(20)micron respectively for those on conservative treatment (n = 12), p = 0.006 (ANOVA for repeated measures).
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Page 8 of 10encouraged to comply with CPAP not just to relieve
daytime sleepiness but there may be cardio-protective
effects. Further studies with the RCT design over short
to medium term are warranted to assess the effect of
CPAP on carotid IMT.
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